Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sexual supplement recall

This article was originally published in The Tan Sheet

Executive Summary

In its latest warning on adulterated supplements sold as treatments for erectile dysfunction, FDA advises consumers not to use Blue Steel or Hero products distributed by Active Nutraceuticals because they are considered unapproved drugs and have not been proven to be safe or effective. The products contain undeclared and unapproved substances similar in chemical structure to sildenafil (Pfizer's Viagra), FDA says. "Because these products are labeled as 'all natural dietary supplements,' consumers may assume that they are harmless and pose no health risk," but the sildenafil may interact with nitrates found in some prescription drugs and can lower blood pressure to dangerous levels, the agency says (1"The Tan Sheet" Jan. 28, 2008, p. 11). Active, a unit of Carrollton, Ga.-based Marion Group, distributes Blue Steel in 10-count bottles or in blister packs and Hero in two-capsule blister packs...

You may also be interested in...



FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says

IGBA Calls For ‘Streamlining’ Of Global Biosimilars Process

The IGBA has called for a “streamlined” global biosimilar development and registration process, with a new policy paper highlighting the limited value of comparative efficacy clinical data at the same time as it urges renewed efforts on educating healthcare professionals.

Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel